Take Ogli 15 mg tablet orally once daily, with or without food. Swallow the tablet whole with a glass of water. Do not crush, chew, or break the tablet.

Oglitriptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by inhibiting the enzyme DPP-4, which is responsible for the inactivation of incretin hormones like Glucagon-Like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Polypeptide (GIP). By preserving active incretins, Oglitriptin enhances glucose-dependent insulin secretion from pancreatic beta cells and reduces glucagon secretion from pancreatic alpha cells, thereby lowering blood glucose levels.

• •History of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) to Oglitriptin or any excipients in the formulation.
• •Type 1 diabetes mellitus.
• •Diabetic ketoacidosis.

Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

In the event of an overdose, discontinue Ogli 15 mg and initiate appropriate supportive treatment. Oglitriptin is unlikely to be removed by hemodialysis or peritoneal dialysis effectively.

Pregnancy Category B/C (Animal studies may show risk, but human data are insufficient. Use only if clearly needed). It is not known whether Oglitriptin is excreted in human milk; caution should be exercised when administered to a nursing woman.